IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Esperion Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
Lundin Law PC announces a class action lawsuit has been filed against Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR) concerning possible violations of federal securities laws between August 18, 2015 and September 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 14, 2016, lead plaintiff motion deadline.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at firstname.lastname@example.org.
According to the complaint, the Company had no clear path to approval for ETC-1002, the Company's lead product candidate designed to lower LDL-cholesterol levels. In addition, the FDA had encouraged the Company to initiate a cardiovascular outcomes trial ("CVOT") and that completion of a CVOT could be necessary prior to approval of ETC-1002.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Lundin Law PC
Brian Lundin, Esq.